In recent years, atezolizumab (PD-L1 inhibitor) combined with paclitaxel chemotherapy has achieved efficacy in PD-L1-positive triple-negative breast cancer (TNBC) patients 3. The gene discussed is CD274; the disease is triple-negative breast carcinoma.